Systems and methods for treatment of hearing using dihexa
US-2024424050-A1 · Dec 26, 2024 · US
US9226914B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9226914-B2 |
| Application number | US-201313942827-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 16, 2013 |
| Priority date | Jul 16, 2013 |
| Publication date | Jan 5, 2016 |
| Grant date | Jan 5, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed are methods for promoting neuronal health and/or development in a subject by providing nutritional compositions comprising docosahexaenoic acid and alpha-lipoic acid. The nutritional composition may further include lactoferrin, a prebiotic, a probiotic, and mixtures thereof. Additionally disclosed are methods for accelerating the development of neuronal activity and/or strengthening electrochemical synapse signaling by providing the nutritional composition(s) disclosed herein to a target subject.
Opening claim text (preview).
What is claimed is: 1. A method for accelerating neuronal activity in a target subject, comprising providing a nutritional composition comprising a carbohydrate source, a fat source, a protein source, docosahexaenoic acid, and alpha-lipoic acid to the target subject, wherein the alpha-lipoic acid is present in an amount of from about 0.1 mg/100 kcal to about 35 mg/100 kcal, and wherein the nutritional composition provides accelerated neuronal activity in the target subject. 2. The method of claim 1 , wherein alpha-lipoic acid is present in an amount from about 10 mg/100 kcal to about 20 mg/100 kcal. 3. The method of claim 1 , wherein docosahexaenoic acid is present in an amount from about 5 mg/100 kcal to about 75 mg/100 kcal. 4. The method of claim 1 , wherein the nutritional composition further comprises sialic acid. 5. The method of claim 4 , wherein sialic acid is present in an amount from about 0.5 mg/100 kcal to about 45 mg/100 kcals. 6. The method of claim 1 , wherein the nutritional composition further comprises a prebiotic. 7. The method of claim 1 , wherein the nutritional composition, when provided to the target subject, acutely affects neuronal activity patterns and strengthens electrochemical synapse connections in the target subject to whom the nutritional composition is provided. 8. The method of claim 1 , wherein the nutritional composition further comprises arachidonic acid. 9. The method of claim 1 , wherein the nutritional composition is an infant formula. 10. A method for accelerating the development of neuronal activity in a target subject comprising providing to the target subject a nutritional composition which comprises per 100 kcal: (i) between about 6 g and about 22 g of a carbohydrate source; (ii) between about 1 g and about 7 g of a protein source; (iii) between about 1.3 g and about 7.2 g of a fat source; (iv) between about 5 mg and about 75 mg of docosahexaenoic acid; and (iv) between about 0.1 mg and about 35 mg of alpha-lipoic acid. 11. The method of claim 10 , wherein the nutritional composition further comprises per 100 kcal between about 0.3 g and about 1.2 g of prebiotic. 12. The method of claim 10 , wherein the nutritional composition further comprises per 100 kcal between about 0.5 mg and about 45 mg of sialic acid. 13. The method of claim 10 , wherein the nutritional composition further comprises per 100 kcal between about 10 mg and about 250 mg of lactoferrin. 14. The method of claim 10 , wherein the nutritional composition further comprises a culture supernatant from a late-exponential growth phase of a probiotic batch-cultivation process. 15. A method for promoting electrochemical synapse signaling in a target subject, comprising providing to a target subject, a nutritional composition comprising a carbohydrate source, a protein source, a fat source, docosahexaenoic acid, and alpha-lipoic acid, wherein alpha-lipoic acid is present in an amount of from about 0.1 mg/100 kcal to about 35 mg/100kcal, and wherein the nutritional composition promotes electrochemical synapse in the target subject. 16. The method of claim 15 wherein the nutritional composition further comprises arachidonic acid. 17. The method of claim 15 , wherein the target subject is a pediatric subject. 18. The method of claim 15 , wherein the nutritional composition is an infant formula. 19. The method of claim 15 , wherein nutritional composition further comprises lactoferrin.
Drugs for disorders of the nervous system · CPC title
Transferrins, e.g. lactoferrins, ovotransferrins · CPC title
Medicinal preparations containing materials or reaction products thereof with undetermined constitution · CPC title
Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula · CPC title
Dietetic milk products not covered by groups A23C9/12 - A23C9/18 · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.